Therapeutics in Active Prostate Cancer Surveillance (TAPS02)
Status:
Not yet recruiting
Trial end date:
2030-07-01
Target enrollment:
Participant gender:
Summary
This is a phase 3, randomised, multicentre, double-blind, placebo-controlled trial
investigating the use of short term androgen deprivation therapy in the form of apalutamide
(Erleada) in men on active surveillance for prostate cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Cambridge University Hospitals NHS Foundation Trust